CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart

被引：1

作者：

Skaar, Todd C. ^{[1
]}

Desta, Zeruesenay ^{[1
]}

机构：

[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

关键词：

BREAST-CANCER; METABOLITE; BIOTRANSFORMATION; GENOTYPE;

D O I：

10.1002/cpt.1039

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.

引用

页码：755 / 757

页数：3

共 50 条

[31] Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen
Zaman, K.
Dahmane, E.
Csajka, C.
Perey, L.
Buclin, T.
Bodmer, A.
Leyvraz, S.
Rindisbacher, M. Galmiche
Berthod, G.
Chin, E.
Decosterd, L.
CANCER RESEARCH, 2010, 70
[32] Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer
Goetz, M. P.
Reinicke, K. E.
Reid, J. M.
Suman, V. J.
Kuffel, M. J.
Safgren, S. L.
Buhrow, S. A.
Reynolds, C. A.
Jenkins, R. B.
Hawse, J. R.
Perez, E. A.
Ingle, J. N.
Ames, M. M.
CANCER RESEARCH, 2009, 69 (24) : 594S - 594S
[33] CYP2D6 polymorphisms associated with tamoxifen outcome
Hutchinson L.
Nature Reviews Clinical Oncology, 2009, 6 (12) : 675 - 675
[34] CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
V. O. Dezentjé
F. L. Opdam
H. Gelderblom
J. Hartigh den
T. Van der Straaten
R. Vree
E. Maartense
C. H. Smorenburg
H. Putter
A. S. Dieudonné
P. Neven
C. J. H. Van de Velde
J. W. R. Nortier
H.-J. Guchelaar
Breast Cancer Research and Treatment, 2015, 153 : 583 - 590
[35] Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Sideras, Kostandinos
Ingle, James N.
Ames, Matthew M.
Loprinzi, Charles L.
Mrazek, David P.
Black, John L.
Weinshilboum, Richard M.
Hawse, John R.
Spelsberg, Thomas C.
Goetz, Matthew P.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2768 - 2776
[36] Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues
Holzman, David
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (20) : 1370 - 1371
[37] The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Ferraldeschi, Roberta
Newman, William G.
PHARMACEUTICALS, 2010, 3 (04) : 1122 - 1138
[38] CYP2D6 and Tamoxifen: Awaiting the Denouement Reply
Rae, James M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4590 - 4591
[39] Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Hertz, Daniel L.
Deal, Allison
Ibrahim, Joseph G.
Walko, Christine M.
Weck, Karen E.
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R.
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M.
Jones, David R.
Desta, Zeruesenay
Flockhart, David A.
Evans, James P.
McLeod, Howard L.
Carey, Lisa A.
Irvin, William J., Jr.
ONCOLOGIST, 2016, 21 (07): : 795 - 803
[40] Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Bedeutung des CYP2D6 Polymorphismus für die Tamoxifen Therapie: eine Standortbestimmung
Ariana E. Huber-Wechselberger
Paul Niedetzky
Irene Aigner
Elisabeth Haschke-Becher
Wiener Medizinische Wochenschrift, 2012, 162 (11-12) : 252 - 261

← 1 2 3 4 5 →